

# *A Landscape of Care*



FOR THE 1<sup>st</sup> QUARTER ENDED 30<sup>th</sup> JUNE 2023

**Consolidated Statement of Profit or Loss and Other Comprehensive Income**

	<b>Group</b>		<b>Company</b>	
	<b>03 Months Ended 30/06/2023 Unaudited Rs. '000</b>	<b>03 Months Ended 30/06/2022 Unaudited Rs. '000</b>	<b>03 Months Ended 30/06/2023 Unaudited Rs. '000</b>	<b>03 Months Ended 30/06/2022 Unaudited Rs. '000</b>
<b>Revenue</b>	<b>2,200,395</b>	<b>1,644,483</b>	<b>1,225,829</b>	<b>906,217</b>
Cost of Sales	(1,003,567)	(620,676)	(566,205)	(342,590)
<b>Gross Profit</b>	<b>1,196,828</b>	<b>1,023,808</b>	<b>659,624</b>	<b>563,627</b>
Other Operating Income	31,607	(13,168)	13,073	8,806
Administrative Expenses	(800,472)	(621,428)	(506,783)	(397,893)
Other Operating Expenses	(305,102)	(196,650)	(155,731)	(120,496)
<b>Results from Operating Activities</b>	<b>122,861</b>	<b>192,562</b>	<b>10,183</b>	<b>54,044</b>
Finance Cost	(44,176)	(15,583)	(35,010)	(12,678)
Finance Income	39,001	65,340	166,291	213,155
<b>Profit before Taxation</b>	<b>117,686</b>	<b>242,319</b>	<b>141,464</b>	<b>254,521</b>
Taxation	(85,025)	(35,314)	(28,758)	(15,145)
<b>Net Profit after Taxation</b>	<b>32,661</b>	<b>207,006</b>	<b>112,706</b>	<b>239,376</b>
<b>Other Comprehensive Income</b>				
<b>Items will not be reclassified to profit or loss</b>				
Net Change in Fair Value on Equity Investments at FVTOCI	(1,738)	(1,880)	(1,755)	1,660
Other Comprehensive Income for the period	(1,738)	(1,880)	(1,755)	1,660
<b>Total Comprehensive Income for the period</b>	<b>30,923</b>	<b>205,125</b>	<b>110,951</b>	<b>241,036</b>
Profit Attributable to:				
Equity Holders of the Parent	19,424	184,299	112,706	239,376
Non-Controlling Interest	13,237	22,706	-	-
	<b>32,661</b>	<b>207,006</b>	<b>112,706</b>	<b>239,376</b>
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent	17,683	183,086	110,951	241,036
Non-Controlling Interest	13,240	22,039	-	-
	<b>30,923</b>	<b>205,125</b>	<b>110,951</b>	<b>241,036</b>
<b>Earnings per Share - Basic</b>	<b>0.54</b>	<b>5.44</b>	<b>3.13</b>	<b>7.12</b>

The above figures are provisional and subject to audit.


**CEYLON HOSPITALS PLC**

Financial Statements for the quarter ended 30th June 2023


**Consolidated Statement of Financial Position**


GROUP COMPANY			GROUP		COMPANY	
Audited	Audited		Unaudited	Unaudited	Unaudited	Unaudited
As at	As at		As at	As at	As at	As at
31/03/2023	31/03/2023		30/06/2023	30/06/2022	30/06/2023	30/06/2022
Rs. '000	Rs. '000		Rs. '000	Rs. '000	Rs. '000	Rs. '000
		ASSETS				
		Non-Current Assets				
7,705,992	4,639,970	Property, Plant and Equipment	7,857,718	7,409,236	4,728,291	4,519,582
2,604,471	2,592,874	Capital Work in Progress	2,921,006	1,228,657	2,894,877	1,228,657
261,135	261,135	Right of Use Assets	231,960	273,264	231,960	273,264
-	1,457,821	Investments in Subsidiary	-	-	1,457,821	1,457,821
286,005	79,181	Other Financial Assets	288,972	304,186	76,780	82,847
-	-	Prepaid Rent	-	1,760	-	-
10,857,603	9,030,981		11,299,656	9,217,103	9,389,729	7,562,170
		Current Assets				
1,020,132	807,593	Inventories	954,985	996,593	754,058	806,117
277,121	154,800	Trade and Other Receivables	388,640	407,511	199,550	199,307
726,559	378,560	Prepayments	658,561	479,569	306,921	286,667
5,329	37,699	Amount Due from Related Parties	4,765	4,399	191,043	34,377
789,484	40,686	Other Financial Assets	730,998	1,551,226	42,924	771,808
13,607	13,262	Tax Refund Due	13,687	13,260	13,342	13,260
420,519	275,221	Cash and Cash Equivalents	391,716	361,135	283,343	124,725
3,252,751	1,707,821		3,143,352	3,813,693	1,791,181	2,236,259
14,110,354	10,738,802	Total Assets	14,443,008	13,030,797	11,180,910	9,798,430
		EQUITY AND LIABILITIES				
		Equity Attributable to Equity holders of the parent				
1,142,798	1,142,798	Stated Capital	1,142,798	916,366	1,142,798	916,366
2,290,344	1,742,664	Revaluation Reserve	2,290,344	2,691,662	1,742,664	2,134,544
76,844	6,312	Fair Value Reserve	75,102	64,655	4,557	2,260
4,261,864	2,812,305	Revenue Reserves	4,198,439	3,888,885	2,842,162	2,765,448
7,771,850	5,704,079		7,706,683	7,561,568	5,732,181	5,818,618
729,500	-	Non-Controlling Interests	708,939	714,061	-	-
8,501,350	5,704,079	Total Equity	8,415,622	8,275,629	5,732,181	5,818,618
		Non-Current Liabilities				
2,135,972	2,468,282	Interest Bearing Loans and Borrowings	2,373,620	1,921,961	2,706,750	1,834,353
-	30,470	Deferred Revenue	-	-	34,368	30,129
205,414	182,727	Retirement Benefit Obligations	208,539	180,747	186,199	158,385
1,301,996	1,004,120	Deferred Tax Liabilities	1,310,997	711,252	1,010,120	452,599
3,643,382	3,685,599		3,893,156	2,813,959	3,937,437	2,475,466
		Current Liabilities				
483,403	387,321	Bank Overdraft	552,409	256,995	468,861	84,960
520,602	478,038	Interest Bearing Loans and Borrowings	503,382	318,314	473,693	268,043
879,180	436,695	Trade and Other Payables	993,265	1,268,600	518,342	774,714
82,437	35,164	Taxation Payable	68,865	83,976	25,366	40,278
-	11,906	Amount Due to Related Parties	16,309	13,322	25,030	336,351
1,965,622	1,349,124		2,134,230	1,941,208	1,511,292	1,504,346
14,110,354	10,738,802	Total Equity and Liabilities	14,443,008	13,030,797	11,180,910	9,798,430

The above figures are provisional and subject to audit.

  
**Thusitha Rubasinghe**  
 Chief Financial Officer

 The Board of Directors is responsible for the preparation and presentation of these Financial Statements.  
 Signed for and on behalf of the Board by,

  
**A E Tudawe**  
 Chairman

  
**U D Tudawe**  
 Director

14th August 2023

**CEYLON HOSPITALS PLC**  
**Consolidated Statement of Changes in Equity**

**Group**

	Attributable to equity holders of the parent					Non-Controlling Interests	Total Equity
	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000		
<b>Balance as at 31st March 2022</b>	916,366	2,691,662	65,868	3,873,950	7,547,846	734,254	8,282,100
Net Profit for the Year	-	-	-	571,831	571,831	79,838	651,669
<b>Other Comprehensive Income</b>							
Deferred Tax Effect on Revaluation Gain	-	(401,318)	-	-	(401,318)	(2,191)	(403,509)
Actuarial Gain on Gratuity Valuation	-	-	-	(17,562)	(17,562)	(368)	(17,930)
Deferred Tax effect on Gratuity Valuation	-	-	-	5,065	5,065	76	5,141
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	10,976	-	10,976	1,222	12,198
<b>Total Comprehensive Income for the Year</b>	-	(401,318)	10,976	559,334	168,991	78,577	247,568
<b>Transactions with Owners in their capacity as Owners</b>							
Shares issued at Rights Issue	226,432	-	-	-	226,432	-	226,432
Rights Issue Expenses	-	-	-	(2,056)	(2,056)	-	(2,056)
Shares issued by the Subsidiary at Rights Issue	-	-	-	-	-	5,860	5,860
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)	(89,190)	(258,554)
	<b>226,432</b>	-	-	<b>(171,420)</b>	<b>55,012</b>	<b>(83,330)</b>	<b>(28,318)</b>
<b>Balance as at 31st March 2023 - Audited</b>	<b>1,142,798</b>	<b>2,290,344</b>	<b>76,844</b>	<b>4,261,864</b>	<b>7,771,850</b>	<b>729,501</b>	<b>8,501,350</b>
Net Profit for the quarter ended 30 June 2023	-	-	-	19,424	19,424	13,237	32,661
<b>Other Comprehensive Income</b>							
Net Gain/ (Loss) on Gratuity Valuation	-	-	(1,741)	-	(1,741)	3	(1,738)
<b>Total Comprehensive Income for the quarter ended 30 June 2023</b>	-	-	(1,741)	<b>19,424</b>	<b>17,683</b>	<b>13,240</b>	<b>30,923</b>
<b>Transactions with Owners in their capacity as Owners</b>							
Rights Issue Expenses	-	-	-	(73)	(73)	-	(73)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)	(33,802)	(116,578)
	-	-	-	<b>(82,849)</b>	<b>(82,849)</b>	<b>(33,802)</b>	<b>(116,651)</b>
<b>Balance as at 30th June 2023</b>	<b>1,142,798</b>	<b>2,290,344</b>	<b>75,102</b>	<b>4,198,439</b>	<b>7,706,683</b>	<b>708,939</b>	<b>8,415,622</b>

**Company**

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000
<b>Balance as at 31st March 2022</b>	916,366	2,134,544	600	2,695,436	5,746,946
Net Profit for the Year	-	-	-	299,238	299,238
<b>Other Comprehensive Income</b>					
Deferred Tax Effect on Revaluation Gain	-	(391,880)	-	-	(391,880)
Actuarial Gain on Gratuity Valuation	-	-	-	(15,641)	(15,641)
Deferred Tax Effect on Gratuity Valuation	-	-	-	4,692	4,692
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	5,712	-	5,712
<b>Total Comprehensive Income for the Year</b>	-	(391,880)	5,712	<b>288,289</b>	<b>(97,879)</b>
<b>Transactions with Owners in their capacity as Owners</b>					
Shares issued at Rights Issue	226,432	-	-	-	226,432
Rights Issue Expenses	-	-	-	(2,056)	(2,056)
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)
	<b>226,432</b>	-	-	<b>(171,420)</b>	<b>55,012</b>
<b>Balance as at 31st March 2023 - Audited</b>	<b>1,142,798</b>	<b>1,742,664</b>	<b>6,312</b>	<b>2,812,305</b>	<b>5,704,079</b>
Net Profit for the quarter ended 30 June 2023	-	-	-	112,706	112,706
<b>Other Comprehensive Income</b>					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(1,755)	-	(1,755)
<b>Total Comprehensive Income for the quarter ended 30 June 2023</b>	-	-	(1,755)	<b>112,706</b>	<b>110,951</b>
<b>Transactions with Owners in their capacity as Owners</b>					
Rights Issue Expenses	-	-	-	(73)	(73)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)
	-	-	-	<b>(82,849)</b>	<b>(82,849)</b>
<b>Balance as at 30th June 2023</b>	<b>1,142,798</b>	<b>1,742,664</b>	<b>4,557</b>	<b>2,842,162</b>	<b>5,732,181</b>

Group

	Attributable to equity holders of the parent					Non Controlling Interests	Total Equity
	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000		
<b>Balance as at 31st March 2021</b>	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,529
Net Profit for the Year	-	-	-	982,324	982,324	127,202	1,109,526
<b>Other Comprehensive Income</b>							
Actuarial Gain on Gratuity valuation	-	-	-	55,965	55,965	300	56,265
Deferred Tax Effect on Gratuity valuation	-	-	-	(6,342)	(6,342)	332	(6,010)
Prior Year Adjustments -Inventory Written off	-	-	-	(989)	(989)	(230)	(1,219)
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,568)	-	(2,568)	217	(2,351)
<b>Total Comprehensive Income for the Year</b>	-	-	(2,568)	1,030,957	1,028,389	127,820	1,156,211
<b>Transactions with Owners in their capacity as Owners</b>							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	127,301	127,301
Share buy-back	-	-	-	(54)	(54)	-	(54)
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,495)	(221,888)
	-	-	-	(108,447)	(108,447)	13,806	(94,641)
<b>Balance as at 31st March 2022 - Audited</b>	916,366	2,691,662	65,868	3,873,950	7,547,846	734,253	8,282,100
Net Profit for the quarter ended 30 June 2022	-	-	-	184,299	184,299	22,706	207,006
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(1,213)	-	(1,213)	(667)	(1,880)
<b>Total Comprehensive Income for the quarter ended 30 June 2022</b>	-	-	(1,213)	184,299	183,086	22,039	205,125
<b>Transactions with Owners in their capacity as Owners</b>							
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)	(42,231)	(211,595)
	-	-	-	(169,364)	(169,364)	(42,231)	(211,595)
<b>Balance as at 30th June 2022</b>	916,366	2,691,662	64,655	3,888,885	7,561,568	714,061	8,275,629

Company

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000
<b>Balance as at 31st March 2021</b>	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit for the Year	-	-	-	770,550	770,550
<b>Other Comprehensive Income</b>					
Actuarial Gain on Gratuity valuation	-	-	-	54,510	54,510
Deferred Tax Effect on Gratuity valuation	-	-	-	(7,631)	(7,631)
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	472	-	472
<b>Total Comprehensive Income for the Year</b>	-	-	472	817,429	817,901
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
	-	-	-	(108,393)	(108,393)
<b>Balance as at 31st March 2022 - Audited</b>	916,366	2,134,544	600	2,695,436	5,746,946
Net Profit for the quarter ended 30 June 2022	-	-	-	239,376	239,376
<b>Other Comprehensive Income</b>					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	1,660	-	1,660
<b>Total Comprehensive Income for the quarter ended 30 June 2022</b>	-	-	1,660	239,376	241,036
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)
	-	-	-	(169,364)	(169,364)
<b>Balance as at 30th June 2022</b>	916,366	2,134,544	2,260	2,765,448	5,818,618

**Consolidated Statement of Cash Flows**

Group	Company		Group	Company		
Audited	Audited		Unaudited	Unaudited		
12 Months	12 Months		03 Months	03 Months		
Ended	Ended		Ended	Ended		
31/03/2023	31/03/2023		30/06/2023	30/06/2022		
Rs '000	Rs '000		Rs '000	Rs '000		
<b>Cash Flows from/ (Used in) Operating Activities</b>						
1,060,324	553,932	Net Profit Before Income Tax Expenses	117,686	242,319	141,464	254,521
		Adjustments for :				
7,018	3,920	Inventory Write-off/(Write in)	10,793	(1,015)	9,986	2,844
68,789	(7,416)	Bad Debts Write-off	450	190	450	190
389,264	212,151	Depreciation Charge	112,213	88,966	54,545	49,080
116,248	116,248	Amortisation of Right of use assets	29,175	27,844	29,175	27,844
(207,247)	(294,804)	Finance Income	(39,001)	(65,340)	(166,291)	(213,155)
87,898	61,999	Finance Cost	44,176	15,583	35,010	12,678
-	(1,000)	Amortisation of Deferred Rent Expenses/(Income)	-	(870)	(473)	(1,343)
(29,970)	(3,546)	Fair value (Gain)/Loss on Financial Instruments	(13,103)	28,347	(250)	(1,208)
-	-	Foreign Exchange (Gain)/Loss	-	1,474	-	5,919
(24,816)	-	Reversal of provisions	-	(29,500)	-	(29,500)
2,171	-	Impairment on Receivables	-	-	-	-
41,212	36,052	Provision for Defined Benefit Plans	10,260	9,750	9,000	8,100
1,510,891	677,536	Operating Profit before Working Capital Changes	272,649	317,748	112,616	115,969
(192,001)	(117,943)	(Increase)/Decrease in Inventories	54,354	(160,428)	43,550	(115,388)
(509,974)	(115,936)	(Increase)/Decrease in Trade and Other Receivables	(44,423)	(329,850)	26,439	(82,074)
(340,724)	(425,754)	Increase/(Decrease) in Trade and Other Payables	114,086	50,207	81,648	(58,236)
(8,194)	(68,393)	(Increase)/Decrease Related Party Dues	16,873	6,059	(140,220)	259,373
459,998	(50,490)	Cash Generated from Operations	413,539	(116,264)	124,033	119,645
(55,683)	(29,784)	Finance Cost Paid	(44,176)	(15,583)	(35,010)	(12,678)
(31,726)	(25,754)	Defined Benefit Plan Costs Paid	(7,135)	(7,001)	(5,528)	(6,505)
(264,363)	(129,869)	Income Tax/WHT Paid	(90,935)	(75,756)	(32,636)	(48,148)
108,226	(235,897)	Net Cash from Operating Activities	271,293	(214,605)	50,859	52,314
<b>Cash Flows from/ (used in) Investing Activities</b>						
(2,218,525)	(1,852,868)	Acquisition of Property, Plant and Equipment	(580,472)	(245,657)	(444,870)	(205,191)
691,749	624,537	(Acquisition)/ Disposal of other Investments	67,732	(161,328)	2,168	(121,083)
207,247	294,804	Income from Investments	39,001	65,340	166,291	213,155
(1,319,529)	(933,527)	Net Cash Flows from/ (used in) Investing Activities	(473,739)	(341,645)	(276,411)	(113,120)
<b>Cash Flows from/ (used in) Financing Activities</b>						
875,000	1,260,000	Receipts from Interest Bearing Loans and Borrowings	300,000	300,000	300,000	300,000
(206,771)	(149,541)	Re-payments to Interest Bearing Loans and Borrowing	(51,080)	(35,324)	(37,385)	(20,719)
(142,916)	(142,916)	Lease Rent Payment	(27,632)	(44,115)	(27,632)	(44,115)
226,432	226,432	Proceeds on Shares issued at Rights Issue	-	-	-	-
5,860	-	Changes in Non-controlling interest on issue of shares by subsidiary	-	-	-	-
(2,056)	(2,056)	Right Issue Expenses	(73)	-	(73)	-
(258,553)	(169,364)	Dividends Paid	(116,578)	(211,595)	(82,776)	(169,364)
496,996	1,022,555	Net Cash Flows from/ (used in) Financing Activities	104,637	8,966	152,134	65,803
(714,307)	(146,868)	Net Increase/ (Decrease) in Cash and Cash Equivalents	(97,809)	(547,283)	(73,418)	4,997
651,423	34,768	Cash and Cash Equivalents at the Beginning of the Year	(62,884)	651,423	(112,100)	34,768
(62,884)	(112,100)	Cash and Cash Equivalents at the End of the Year	(160,693)	104,140	(185,518)	39,765
<b>Analysis of Cash and Cash Equivalents</b>						
(483,403)	(387,321)	Bank Overdraft	(552,409)	(256,995)	(468,861)	(84,960)
420,519	275,221	Cash in Hand and at Bank	391,716	361,135	283,343	124,725
(62,884)	(112,100)		(160,693)	104,140	(185,518)	39,765

## Explanatory Notes

## 01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

## 02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the quarter ended 30 June 2023, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

## 03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the quarter ended 30 June 2023 were authorised for issue by the Board of Directors on 14th August 2023.

## 04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

## 4.1 Basis of preparation

The interim financial statements for the quarter ended 30 June 2023 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 March 2023.

## 4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 30 June 2023 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

## 05. Capital Commitments

The Project 2022 undertaken in FY 2018/19 is now nearing completion. The Main Constructor for the Project 2022 is M/s Tudawe Brothers (Pvt) Ltd that is a Related Party to the Company.

06. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements other than what is disclosed in the Annual Report 2022/2023.

## 07. Events occurring after the Balance Sheet date

There have been no material events subsequent to the reporting date which require disclosures/adjustments in these financial statements.

08. The Company paid an interim dividend of Rs. 2.30 per share amounting to Rs. 82,776,474/- on the issued shares as at 31.03.2023. The payment was done on 09th June 2023. The company received Rs. 163 Mn as dividends from its subsidiaries.

09. Related party transactions for the quarter ended 30 June 2023 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

## Related Party Transactions

For the quarter ended 30 June 2023 - In Rs. '000

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Durdans Management Services Ltd	Ultimate Parent	Management fee	Recurrent	11,879
		Dividend paid	Recurrent	49,584
		<b>Total</b>		<b>61,463</b>
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	10,035
		Rendering of medical services	Recurrent	40,211
		Sharing of utilities and other cost	Recurrent	157,544
		Dividend Received	Recurrent	138,646
		Purchases of Drugs and consumables	Recurrent	20,246
		Receiving of medical services	Recurrent	58,674
		Receiving of utilities and other cost	Recurrent	150
		<b>Total</b>		<b>425,506</b>
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	1,386
		Rendering of medical services	Recurrent	7,618
		Sharing of utilities and other cost	Recurrent	31,475
		Dividend Received	Recurrent	23,860
		Purchases of Drugs and consumables	Recurrent	1,660
		Receiving of medical services	Recurrent	655
		<b>Total</b>		<b>66,654</b>
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rent Received	Recurrent	5,692
		<b>Total</b>		<b>5,692</b>
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Purchases of Drugs and consumables	Recurrent	46,149
		<b>Total</b>		<b>46,149</b>

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Tudawe Brothers (Pvt) Ltd	Affiliate	Project 2022 Construction Cost	Non Recurrent	256,577
		<b>Total</b>		<b>256,577</b>
Tudawe Engineering Services (Pvt) Ltd	Affiliate	Project 2022 Construction Cost	Non Recurrent	27,750
		<b>Total</b>		<b>27,750</b>

**Share Information**
**Number of Shares Represented in Stated Capital**

Voting Shares	27,122,726
Non-Voting Shares	8,867,044
Total	<b>35,989,770</b>

**Public Shareholding as at 30th June 2023**

	Voting	Non-Voting
Number of shareholders	2,362	1,311
Number of shares	5,948,582	4,524,592
Holding Percentage	21.93%	51.03%
Float Adjusted Market Capitalisation (Rs Mn)	712	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

**Directors' and Chief Executive Officer's Shareholding as at 30th June 2023**

	Number of Shares	
	Voting	Non-Voting
Mr. A. E. Tudawe	235,152	-
Mr. U. D. Tudawe	181,279	-
Dr A. D. P. A. Wijegoonewardene	234,368	-
Mr. Y. N. R. Piyasena	527,567	-
Mr. A. S. Abeyewardene	1,530	1,275
Mr. A. D. B. Talwatte	1,062	-
Mr. A.V.R. De Silva Jayatilleke	106	-
Mr. A.S. Tudawe	51	1,062

**Market Prices recorded during the Quarter**

	Highest Traded Price		Lowest Traded Price		Last Traded Price	
	2023/24	2022/23	2023/24	2022/23	2023/24	2022/23
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
Voting	138.75 03/04/2023	139.00 08/06/2022	110.00 16/06/2023	100.00 27/04/2022	119.75 27/06/2023	117.50 30/06/2022
Non - Voting	119.00 26/06/2023	115.00 23/05/2022	96.00 03/04/2023	81.00 19/05/2022	113.00 28/06/2023	98.90 28/06/2022

**Per Share Ratios**

	Group		Company	
	As at 30/06/2023 Rs.	As at 30/06/2022 Rs.	As at 30/06/2023 Rs.	As at 30/06/2022 Rs.
Earnings Per Share	0.54	5.44	3.13	7.12
Net Asset Per Share	214.14	223.23	159.27	171.78

**Top 20 Shareholders Listed as at 30 June 2023**
**Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	18,628,342	68.68
Lawrance Tudawe Management Services (Pvt) Ltd	do	637,581	2.35
Mr. Y. N. R. Piyasena	do	527,567	1.95
Mr. D.G. Wijemanna	do	522,328	1.93
Mr. Deen Mohamed Fazal Aslam	do	515,000	1.90
Mr. R.P. Weerasooriya	do	507,994	1.87
Galle Face Capital Partners PLC	do	447,774	1.65
Mr. Merrill J. Fernando	do	390,500	1.44
Cargo Boat Development Company PLC	do	324,577	1.20
MJF Holdings (Pvt) Ltd	do	287,917	1.06
Mr. A. E. Tudawe	do	235,152	0.87
Dr. A. D. P. A. Wijegoonewardene	do	234,368	0.86
Mr. U. D. Tudawe	do	181,279	0.67
Mr. H. L. Tudawe	do	175,433	0.65
Mr. A. D. Tudawe	do	172,108	0.63
Mr. P.V. Tudawe	do	166,789	0.61
Mr. A. H. Munasinghe	do	96,624	0.36
Commercial Bank of Ceylon PLC A/C No. 04	do	88,187	0.33
Merrill J Fernando & Sons (Pvt) Ltd	do	80,914	0.30
Mr. G. A. Tudawe	do	77,576	0.29
		<b>24,298,010</b>	<b>89.59</b>

**Non-Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	2,929,948	33.04
Employees' Provident Fund	do	1,154,371	13.02
MJF Holdings (Pvt) Ltd	do	636,061	7.17
E W Balasuriya & Co. (Pvt) Ltd	do	351,282	3.96
Mr. D. Ratnayake	do	156,045	1.76
Tudawe Engineering Services (Pvt) Ltd	do	97,735	1.10
Mr. D. A. Cabraal	do	87,656	0.99
Mr. S. S. Sithambaranathan	do	82,612	0.93
Mr. A. H. Munasinghe	do	80,000	0.90
Mr. A. D. Tudawe	do	75,597	0.85
Mr. P. S. De Mel	do	75,248	0.85
Ms. T. T. Weerasinghe	do	70,485	0.79
Commercial Bank of Ceylon PLC A/C No. 04	do	64,918	0.73
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	63,750	0.72
Mr. D.P. L. De Mel	do	62,589	0.71
Saman Villas Limited	do	62,115	0.70
Mr. G. D. M. Ranasinghe	do	53,620	0.60
Mr.D.G. Wijemanna	do	53,264	0.60
Mr. H. A. Cabraal	do	53,125	0.60
Mr. U. D. Wickremesooriya	do	53,125	0.60
		<b>6,263,546</b>	<b>70.64</b>

## **CEYLON HOSPITALS PLC**

### **CORPORATE INFORMATION**

**Name of Company**

Ceylon Hospitals PLC

**Brand Name**

DURDANS

**Legal Form**

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

**Company Registration Number**

PQ 113

**Stocks Exchange Listing**

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

**Registered Office**

No.03, Alfred Place, Colombo 03.

**Bankers**

Bank of Ceylon  
Commercial Bank of Ceylon PLC  
DFCC Bank PLC  
Hatton National Bank PLC  
National Development Bank PLC  
Nations Trust Bank PLC  
Sampath Bank PLC  
Seylan Bank PLC  
Union Bank of Colombo PLC  
People's Bank

**Auditors**

Messers.B.R.De.Silva & Co.  
Chartered Accountants  
No. 22/4, Vijaya Kumaratunga Mawatha  
Colombo 05.

**Lawyers**

Mr. D.F.R. Jayamaha  
Hector Jayamaha Law Office,  
No.228,Thimbirigasyaya Road,  
Colombo 05.

**Secretaries**

Nexia Corporate Consultants (Pvt) Ltd  
No. 130, Level 02, Nawala Road,  
Narahenpita. Colombo 05.

**Registrars**

S S P Corporate Services (Pvt) Ltd  
546, Galle Road,  
Colombo 03.